Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NANT Pancreatic Cancer Vaccine in Advanced Pancreatic Cancer
NCT03586869Phase 2Terminated
- Sponsor
- ImmunityBio, Inc.
- Start
- Jul 2018
- Primary completion
- Apr 2019
- Modality
- Adenoviral Vectors, DNA Vaccines, Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of aldoxorubicin, nogapendekin alfa inbakicept, haNK, ETBX-011, ETBX-021 and 5 more in pancreatic adenocarcinoma (PDAC), sponsored by ImmunityBio, Inc. Primary endpoint: Treatment-emergent Adverse Events and Serious Adverse Events up to 230 days. Started Jul 2018; status: terminated.
02
Drugs
aldoxorubicinnogapendekin alfa inbakicepthaNKETBX-011ETBX-021
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03586869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03586869.